Bottom Fish Stocks (between .10 and$10)

[Katfish]

STLT - .58 Stock to watch.

Spotlight Innovation Backs Promising Glaucoma Treatment with Strategic Investment in Solx, Inc.

SANTA MONICA, CA , Dec. 5, 2016 /PRNewswire/ - Online Media Group Covers Spotlight Innovation (OTCQB: STLT)

Spotlight Innovation, Inc. recently announced that it has made a strategic investment in Solx, Inc. , a Massachusetts -based, privately held medical device company. Principally backed by MVM Life Science Partners, LLP , a leading global life science venture capital firm, Solx develops innovative surgical technologies that treat glaucoma, the second leading cause of blindness in the world.

Spotlight Innovation identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging, and neglected diseases. With its investment in Solx, Spotlight Innovation recognizes a unique opportunity to improve the lives of patients suffering from refractory glaucoma.

Solx's lead product is the SOLX Gold Shunt™, a first-in-class, implantable drainage device designed to safely reduce elevated intraocular pressure (IOP) associated with refractory glaucoma without creating a bleb, a common source of complications associated with the current therapies. The device provides a pathway for the flow of aqueous humor from the anterior chamber to the suprachoroidal space, utilizing a natural pressure differential within the eye. The SOLX Gold Shunt is approved for use in Canada and Europe . It has been tested in a multicenter clinical trial and is investigational and awaiting FDA approval in the U.S.

In addition to its external investment in Solx, Spotlight Innovation has an internal development pipeline that includes product candidates for cancer, chronic pain, Zika virus infection, and spinal muscular atrophy (SMA).

To learn more about Spotlight Innovation , interested parties are encouraged to visit the Company's website at: http://www.spotlightinnovation.com.